Stay updated with breaking news from Brca Mutation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation.
Denver resident Jen Masket-Valenta went through a prophylactic double mastectomy last year due to her high risk of being diagnosed with breast cancer. In the wake of those two surgeries
Denver resident Jen Masket-Valenta went through a prophylactic double mastectomy last year due to her high risk of being diagnosed with breast cancer. In the wake of those two surgeries
Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.
Burak Zeybeck, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.